The Clinical Research Priority Program (CRPP) "ImmunoCure" has been established in 2019 and is funded by the University of Zurich.
The CRPP is chaired by Prof. Dr. Patrick Roth and co-chaired by Prof. Dr. Markus G. Manz.
ImmunoCure is a consortium of research groups aiming at the development of novel immunotherapeutic strategies for various types of cancer including brain tumors and hematological malignancies. A major focus of the program is the development of genetically engineered immune cells as well as other antibody-based constructs which can be used as therapeutic weapons against tumors.
We will investigate the therapeutic activity as well as safety profiles of CAR T cells and other antibody-based immunotherapeutic strategies in appropriate preclinical models and subsequently aim at translating these treatment options to the clinical setting, e.g., in clinical phase I studies.